Biopharmaceutical company Verastem Oncology (Nasdaq:VSTM) on Friday announced two-year median follow-up results from the Phase 2 RAMP 201 clinical trial of Avmapki Fakzynja combination therapy (avutometinib capsules and defactinib tablets), showing durable efficacy and manageable safety in recurrent low-grade serous ovarian cancer.

The findings will be presented during an oral plenary session at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting on Women's Cancers taking place in San Juan, Puerto Rico, from 10-13 April 2026.

Patients in the trial demonstrated sustained clinical benefit at a median follow-up of 24.9 months, with 50% of those with KRAS mutations and 30% with KRAS wild-type remaining on therapy for more than one year.

Safety outcomes remained consistent with the primary analysis, with no new safety signals observed. The discontinuation rate due to adverse events was 12%, with adverse events described as manageable in long-term administration.

Exposure-response analysis indicated the strongest therapeutic effect at the FDA-approved dosing regimen of avutometinib 3.2 mg twice weekly plus defactinib 200 mg twice daily. Verastem noted that although lower dosing may improve tolerability, it may also reduce efficacy.